Japan has cautiously eased regulatory requirements related to novel drugs for rare diseases, with the Ministry of Health, Labour and Welfare (MHLW) to allow approval filings without data from Japanese clinical trials under certain conditions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?